Ampicillin Dose for Early and Late-Onset Group B Streptococcal Disease in Neonates

Sin Yin Lim1, Jamie L Miller2

  • 1Division of Pharmacy Practice, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin.

Insights

New guidelines offer ampicillin dosing for neonatal group B streptococcal disease, but evidence is lacking for meningitis treatment. High doses may increase seizure risk.

Area of Science:

  • Neonatal pharmacotherapy
  • Infectious disease management
  • Pediatric pharmacology

Background:

  • Ampicillin is a primary treatment for neonatal group B streptococcal (GBS) infections.
  • Recent American Academy of Pediatrics (AAP) guidelines updated ampicillin dosing for GBS bacteremia and meningitis.
  • The rationale and evidence supporting these updated dosing recommendations were not explicitly provided.

Purpose of the Study:

  • To review the literature on ampicillin pharmacokinetics (PK), pharmacodynamics (PD), and safety in neonates.
  • To identify the evidence supporting current ampicillin dosing recommendations for GBS disease in neonates.
  • To evaluate the safety and efficacy of high-dose ampicillin for neonatal meningitis.

Main Methods:

  • Literature search for studies on ampicillin PK, PD, and safety in neonates.
  • Analysis of existing publications supporting the 2018 Red Book and 2019 AAP guidelines.
  • Review of studies on ampicillin cerebrospinal fluid concentrations and associated adverse events.

Main Results:

  • Evidence supports ampicillin dosing for neonatal GBS bacteremia, with adjustments for postnatal age.
  • No direct evidence was found to support the increased ampicillin dosing recommendations for neonatal GBS meningitis.
  • A single study on cerebrospinal fluid ampicillin concentrations suggested lower doses than currently recommended, raising concerns about supratherapeutic levels and seizure risk.

Conclusions:

  • Current ampicillin dosing for neonatal GBS meningitis lacks robust supporting evidence.
  • High-dose ampicillin for meningitis may lead to adverse events, including seizures, without proven efficacy.
  • Further research is needed to establish optimal and safe ampicillin dosing strategies for neonatal GBS meningitis.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
130
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
173
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
126
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
133
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
155
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
110